Physician profile
Gurpreet D Singh
NPI 1669475919
$7,254.36
in general payments reported to CMS, 2019-2025
33 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $409 · 2021: $1,939 · 2022: $697 · 2023: $1,133 · 2024: $771 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972 · Travel and Lodging: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.88 |
| Travel and Lodging | $749.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $1,396.16 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $934.19 | 2019-2025 | Cequa |
| Zimmer Biomet Holdings, INC. | $827.73 | 2025 | Rosa |
| Abbvie INC. | $476.08 | 2022-2024 | Xen Glaucoma Treatment System, Alphagan P, Lumigan |
| Allergan, INC. | $476.06 | 2019-2022 | |
| Glaukos Corporation | $454.13 | 2020-2025 | Photrexa Viscous and Photrexa, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $400.69 | 2019-2021 | |
| Alcon Vision LLC | $379.06 | 2019-2025 | Clareon, Argos, Rocklatan |
| Ocular Therapeutix, INC. | $348.06 | 2021-2025 | Dextenza |
| Oyster Point Pharma, INC. | $141.28 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $131.94 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $126.80 | 2022-2025 | Miebo, Lotemax Sm, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $116.68 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $115.04 | 2019-2022 | |
| Rxsight INC | $107.23 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $102.62 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $98.33 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $66.45 | 2023 | Visumax |
| Horizon Therapeutics Plc | $66.12 | 2021-2023 | Tepezza |
| Harrow Eye, LLC | $61.20 | 2024-2025 | Vevye |
| Merz North America, INC. | $58.56 | 2019 | |
| Sight Sciences, INC. | $47.28 | 2021-2024 | Omni Surgical System |
| Thea Pharma INC. | $46.81 | 2024-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $39.40 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $34.55 | 2019 | |
| Mallinckrodt Hospital Products INC. | $33.24 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $31.51 | 2021-2023 | Tecnis Iol |
| Insmed, INC. | $28.59 | 2023 | Arikayce |
| Merz Pharmaceuticals, LLC | $25.83 | 2023 | Xeomin |
| New World Medical,INC. | $24.57 | 2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Rayner Intraocular Lenses Limited | $21.27 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Dompe US, INC. | $19.53 | 2021 | |
| Shire North American Group INC | $17.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.